Harmony Biosciences Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule10b5-1 Trading Arrangements
On February 26, 2025, Andrew Serafin, Chief Strategy Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 50,000 shares of the Company’s common stock related to the exercise of options, beginning on May 28, 2025 and continuing until May 31, 2026.
On February 28, 2025, Jeffrey Dierks, theformer Chief Commercial Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 48,765 shares of the Company’s common stock related to the exercise of options, and (ii) an indeterminable number of shares of the Company’s common stock that will depend on the number of shares sold to cover tax withholding obligations in connection with the vesting of 45,000 restricted stock units previously granted, beginning on July 1, 2025 and continuing until December 1, 2025. This plan wasterminated on March 31, 2025.
On March 4, 2025, Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 25,000 shares of the Company’s common stock related to the exercise of options, and (ii) up to 25,000 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, beginning on July 1, 2025 and continuing until December 31, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.